Based on our results regarding the protective effects of low BCP concentrations and their higher potency and also efficacy than a high concentration of BCP [14,15], we hypothesized that the low dose of BCP probably exerts curative and ameliorative effects in the MS treatment. This evidence concerns the gene OPN1SW and myeloid sarcoma.